

Jasmohan Bajaj

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9540416/jasmohan-bajaj-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298
papers

16,412
citations

68
h-index

121
g-index

352
ext. papers

20,963
ext. citations

5.9
avg, IF

7.16
L-index

#	Paper	IF	Citations
298	Acute-on-Chronic Liver Failure Clinical Guidelines.. <i>American Journal of Gastroenterology</i> , 2022 , 117,	0.7	4
297	Circulating microbiome in patients with portal hypertension.. <i>Gut Microbes</i> , 2022 , 14, 2029674	8.8	1
296	QuickStroop, a Shortened Version of EncephalApp, Detects Covert Hepatic Encephalopathy with Similar Accuracy within One Minute.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
295	Promises of microbiome-based therapies.. <i>Journal of Hepatology</i> , 2022 , 76, 1379-1391	13.4	2
294	Microbial Therapeutics in Liver Disease 2021 ,		0
293	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 336-346	0.7	2
292	Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. <i>Gut Microbes</i> , 2021 , 13, 1993584	8.8	0
291	Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	1
290	Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2626-2635.e7	6.9	5
289	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3612-3618	4	5
288	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1661-1669.e2	6.9	4
287	Focused Education Increases Hepatocellular Cancer Screening in Patients with Cirrhosis Regardless of Functional Health Literacy. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2603-2609	4	1
286	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , 2021 , 27, 1343-1347	4.5	8
285	Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. <i>Liver Transplantation</i> , 2021 , 27, 629-640	4.5	5
284	Perspectives of Inpatients With Cirrhosis and Caregivers on Using Health Information Technology: Cross-sectional Multicenter Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e24639	7.6	1
283	Periodontitis is associated with increased liver fibrosis in a population-based cohort of US adults. <i>GastroHep</i> , 2021 , 3, 179-184	1	0
282	Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4

281	Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis. <i>Frontiers in Physiology</i> , 2021 , 12, 702646	4.6	0
280	Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	3
279	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , 2021 , 384, 2317-2330	59.2	14
278	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021 , 74, 1660-1673	11.2	20
277	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
276	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
275	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021 , 74, 2699-2713	11.2	8
274	Fibrosis-4 Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021 , 5, 1605-1615	6	1
273	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S67-S81	13.4	23
272	Liver Transplant Is Associated with Sustained Improvement in Tandem Gait and Risk of Falls. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1360-1366	4	1
271	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 263-272	4	4
270	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 565-572.e5	6.9	3
269	A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder. <i>Hepatology</i> , 2021 , 73, 1688-1700	11.2	46
268	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021 , 70, 531-536	19.2	94
267	Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021 , 74, 80-88	13.4	3
266	Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. <i>Gut</i> , 2021 , 70, 1162-1173	19.2	25
265	Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. <i>Gastroenterology</i> , 2021 , 160, 556-572	13.3	17
264	Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. <i>United European Gastroenterology Journal</i> , 2021 , 9, 193-202	5.3	3

263	Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of Share 35 Rule: An analysis from the UNOS database. <i>Annals of Hepatology</i> , 2021 , 23, 100288	3.1	2
262	Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials. <i>Hepatology Communications</i> , 2021 , 5, 258-271	6	11
261	The Influence of the Microbiome on NAFLD and NASH. <i>Clinical Liver Disease</i> , 2021 , 17, 15-18	2.2	8
260	Is it time to spit? More evidence for the oral-gut-liver axis in liver disease. <i>Hepatology International</i> , 2021 , 15, 4-5	8.8	1
259	Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
258	REPLY. <i>Hepatology</i> , 2021 , 74, 2916-2917	11.2	
257	Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. <i>Gastroenterology</i> , 2021 , 161, 508-521.e7	13.3	9
256	Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access. <i>Liver Transplantation</i> , 2021 , 27, 1830-1843	4.5	1
255	MELD 3.0: One Small Step for Womankind or One Big Step for Everyone?. <i>Gastroenterology</i> , 2021 ,	13.3	1
254	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2021 ,	4.5	3
253	Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis. <i>Gut Microbes</i> , 2021 , 13, 1953247	8.8	3
252	High-Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Hepatology Communications</i> , 2021 , 5, 446-460	6	1
251	Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease.. <i>Comprehensive Physiology</i> , 2021 , 12, 2719-2730	7.7	0
250	Is There Evidence of the Hawthorne Effect in Quality Improvement of Nutritional Consultation in Inpatients With Cirrhosis?. <i>Liver Transplantation</i> , 2020 , 26, 1049-1051	4.5	2
249	Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. <i>Liver International</i> , 2020 , 40, 1395-1407	7.9	7
248	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2571-2579	4	5
247	Reply to: " You know my name, but not my story" Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm. <i>Journal of Hepatology</i> , 2020 , 72, 1213-1214	13.4	0
246	Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. <i>GastroHep</i> , 2020 , 2, 79-86	1	4

245	What diet should I recommend my patient with Hepatic Encephalopathy?. <i>Current Hepatology Reports</i> , 2020 , 19, 13-22	1	3
244	Microbiome: Emerging Concepts in Patients with Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2020 , 24, 493-520	4.6	2
243	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020 , 115, 989-1002	0.7	25
242	Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , 2020 , 72, 1747-1757	11.2	20
241	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. <i>Journal of Hepatology</i> , 2020 , 72, 1003-1027	13.4	65
240	Cognitive Function in Liver Transplantation. <i>Current Transplantation Reports</i> , 2020 , 7, 31-37	1.5	0
239	Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 3008-3016.e2	6.9	17
238	The Gut Microbiome and Liver Disease 2020 , 1062-1068		0
237	Infections in Critically Ill Cirrhosis Patients 2020 , 105-122		
236	Role of gut microbiota in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, G84-G98	5.98	35
235	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. <i>American Journal of Gastroenterology</i> , 2020 , 115, 783-785	0.7	7
234	Characterizing patient-reported outcomes in veterans with cirrhosis. <i>PLoS ONE</i> , 2020 , 15, e0238712	3.7	0
233	Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. <i>Journal of Hepatology</i> , 2020 , 73, 1526-1547	13.4	58
232	Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. <i>Nature Communications</i> , 2020 , 11, 4982	17.4	67
231	Training of hepatology providers improves the screening and resultant interventions for alcohol use disorder. <i>Liver International</i> , 2020 , 40, 2090-2094	7.9	2
230	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020 , 159, 1715-1730.e12	13.3	24
229	Transmitting Diet-Related Microbial Benefit through Fecal Microbiota Transplant in NASH: Can Microbiota Cut Through the Fat?. <i>Hepatology Communications</i> , 2020 , 4, 1559-1561	6	0
228	What Role Should Acute-on-Chronic Liver Failure Play in Liver Transplant Prioritization? A Survey of US-Based Transplant Providers. <i>Liver Transplantation</i> , 2020 , 26, 1658-1661	4.5	3

227	Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. <i>Implementation Science</i> , 2020 , 15, 92	8.4	4
226	Fecal microbial transplant reduces short-term cravings, improves quality of life and microbial diversity in cirrhosis and alcohol use disorder: a randomized, placebo-controlled, clinical trial. <i>Journal of Hepatology</i> , 2020 , 73, S59-S60	13.4	4
225	Validation of a Simple Quality-of-Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy. <i>Hepatology Communications</i> , 2020 , 4, 1353-1361	6	4
224	Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. <i>Hepatology</i> , 2020 , 71, 611-626	11.2	43
223	Hospitalized Women With Cirrhosis Have More Nonhepatic Comorbidities and Associated Complications Than Men. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 3046-3048	6.9	3
222	Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis. <i>Liver International</i> , 2020 , 40, 416-427	7.9	7
221	Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, G661-G669	5.1	27
220	Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. <i>Journal of Digestive Diseases</i> , 2019 , 20, 547-556	2.3	21
219	Serum and urinary metabolomics and outcomes in cirrhosis. <i>PLoS ONE</i> , 2019 , 14, e0223061	3.7	9
218	Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019 , 189, 36-47	5.1	17
217	Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. <i>Drugs</i> , 2019 , 79, 11-16	12.1	28
216	SAT-014-Efficacy of rifaximin soluble solid dispersion in patients with early decompensated cirrhosis and a Conn score of 0: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. <i>Journal of Hepatology</i> , 2019 , 70, e631	13.4	2
215	Altered gut-liver axis in liver diseases. <i>Liver Research</i> , 2019 , 3, 1-2	4.1	
214	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1518-1527	6.1	22
213	Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. <i>Hepatology</i> , 2019 , 70, 1690-1703	11.2	106
212	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019 , 25, 870-880	4.5	22
211	Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1843-1850	4	11
210	Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis. <i>Hepatology</i> , 2019 , 70, 1317-1335	11.2	83

209	Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis. <i>Gastroenterology</i> , 2019 , 156, 1921-1923.e3	13.3	70
208	Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. <i>Hepatology</i> , 2019 , 70, 450-451	11.2	4
207	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. <i>Liver Transplantation</i> , 2019 , 25, 571-579	4.5	30
206	Alterations in Skin Microbiomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2581-2591.e15	6.9	8
205	Nutritional Assessment in Inpatients With Cirrhosis Can Be Improved After Training and Is Associated With Lower Readmissions. <i>Liver Transplantation</i> , 2019 , 25, 1790-1799	4.5	18
204	Reply. <i>Liver Transplantation</i> , 2019 , 25, 1586-1587	4.5	
203	Reply. <i>Gastroenterology</i> , 2019 , 157, 902-903	13.3	
202	Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection. <i>Clinical Liver Disease</i> , 2019 , 14, 107-111	2.2	17
201	Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. <i>JCI Insight</i> , 2019 , 4,	9.9	31
200	Diagnosis and Treatment of Hepatic Encephalopathy. <i>Gastroenterology and Hepatology</i> , 2019 , 15, 434-436	7	1
199	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 599-606	0.7	8
198	Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1080-1090	0.7	27
197	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1091-1100	0.7	15
196	Altered Microbiome in Patients With Cirrhosis and Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 307-321	6.9	64
195	Effect of Increasing Age on Brain Dysfunction in Cirrhosis. <i>Hepatology Communications</i> , 2019 , 3, 63-73	6	4
194	Alcohol, liver disease and the gut microbiota. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 235-246	24.2	199
193	Bile Acid 7 β -Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit <i>Clostridium difficile</i> : Role of Secondary Bile Acids. <i>Cell Chemical Biology</i> , 2019 , 26, 27-34.e4	8.2	69
192	Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. <i>Metabolic Brain Disease</i> , 2019 , 34, 289-295	3.9	15

191	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 756-765.e3	6.9	50
190	Telehealth-Based Evaluation Identifies Patients Who Are Not Candidates for Liver Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 207-209.e1	6.9	19
189	Assessment of the spectrum of hepatic encephalopathy: A multicenter study. <i>Liver Transplantation</i> , 2018 , 24, 587-594	4.5	15
188	Alterations in gut microbial function following liver transplant. <i>Liver Transplantation</i> , 2018 , 24, 752-761	4.5	35
187	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , 2018 , 68, 1621-1632	11.2	65
186	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. <i>Hepatology</i> , 2018 , 68, 1549-1558	11.2	70
185	Reply. <i>Hepatology</i> , 2018 , 68, 791	11.2	
184	Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. <i>Hepatology</i> , 2018 , 68, 599-615	11.2	80
183	Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. <i>Alcoholism: Clinical and Experimental Research</i> , 2018 , 42, 660-667	3.7	15
182	Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. <i>Hepatology</i> , 2018 , 68, 234-247	11.2	59
181	Brain Integrity Changes Underlying Cognitive and Functional Recovery Postliver Transplant Continue to Evolve Over 1 Year. <i>Transplantation</i> , 2018 , 102, 461-470	1.8	5
180	Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. <i>Journal of Clinical and Experimental Hepatology</i> , 2018 , 8, 109-115	4.1	7
179	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. <i>American Journal of Gastroenterology</i> , 2018 , 113, 556-563	0.7	52
178	Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 481-485	4	2
177	Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis. <i>Hepatology</i> , 2018 , 68, 224-233	11.2	15
176	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018 , 67, 2367-2374	11.2	122
175	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. <i>Digestive and Liver Disease</i> , 2018 , 50, 741-749	3.3	15
174	Hepatic encephalopathy: classification and treatment. <i>Journal of Hepatology</i> , 2018 , 68, 838-839	13.4	9

173	Fungal dysbiosis in cirrhosis. <i>Gut</i> , 2018 , 67, 1146-1154	19.2	69
172	Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 78-85	6.1	30
171	C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. <i>Hepatology</i> , 2018 , 67, 1441-1457	11.2	31
170	Associations between Religiosity, Spirituality, and Happiness among Adults Living with Neurological Illness. <i>Geriatrics (Switzerland)</i> , 2018 , 3,	2.2	6
169	Current Management of Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1600-1612	16.2	29
168	Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, G824-G837	5.1	37
167	Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1177-1186	0.7	65
166	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1339	0.7	21
165	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. <i>Gut</i> , 2018 , 67, 918-930	19.2	71
164	Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 94-95	2.9	
163	Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. <i>JCI Insight</i> , 2018 , 3,	9.9	26
162	Predicting Hepatic Encephalopathy-Related Hospitalizations Using a Composite Assessment of Cognitive Impairment and Frailty in 355 Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1506-1515	0.7	22
161	Reply. <i>Hepatology</i> , 2018 , 68, 2046-2048	11.2	
160	Reply. <i>Hepatology</i> , 2018 , 68, 1206	11.2	1
159	Definition and Changes in Nomenclature of Hepatic Encephalopathy 2018 , 1-13		
158	Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1786-1791.e1	6.9	29
157	Gut Microbiota and Complications of Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2017 , 46, 155-169	4.4	54
156	Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. <i>Liver Transplantation</i> , 2017 , 23, 907-914	4.5	57

155	Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. <i>Hepatology Communications</i> , 2017 , 1, 61-70	6	27
154	Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines. <i>Clinical Liver Disease</i> , 2017 , 9, 48-51	2.2	0
153	Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1173-1179	4	6
152	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017 , 67, 1084-1103	13.4	199
151	Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1103-1110	0.7	40
150	The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. <i>Liver International</i> , 2017 , 37, 1843-1851	7.9	27
149	No Association Between Quick Sequential Organ Failure Assessment and Outcomes of Patients With Cirrhosis and Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1803-1804	6.9	4
148	The Human Gut Microbiome in Liver Diseases. <i>Seminars in Liver Disease</i> , 2017 , 37, 128-140	7.3	22
147	Adventures in Developing an App for Covert Hepatic Encephalopathy. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e85	4.2	6
146	Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 794-800	4	13
145	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 768-776	4	14
144	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology</i> , 2017 , 66, 1727-1738	11.2	307
143	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. <i>Nature Communications</i> , 2017 , 8, 837	17.4	118
142	Overt hepatic encephalopathy impairs learning on the EncephalApp stroop which is reversible after liver transplantation. <i>Liver Transplantation</i> , 2017 , 23, 1396-1403	4.5	10
141	Continued Alcohol Misuse in Human Cirrhosis is Associated with an Impaired Gut-Liver Axis. <i>Alcoholism: Clinical and Experimental Research</i> , 2017 , 41, 1857-1865	3.7	56
140	Reply. <i>Hepatology</i> , 2017 , 66, 1355-1356	11.2	
139	Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e108	4.2	32
138	Covert Hepatic Encephalopathy: Can My Patient Drive?. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 118-126	3	12

137	A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. <i>Hepatology</i> , 2017 , 65, 217-224	11.2	55
136	Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 266-272.e1	6.9	30
135	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 565-574.e4	6.9	69
134	Gut microbiome and liver disease. <i>Translational Research</i> , 2017 , 179, 49-59	11	58
133	Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 319-331	6.1	85
132	Microbiota, cirrhosis, and the emerging oral-gut-liver axis. <i>JCI Insight</i> , 2017 , 2,	9.9	91
131	Clinical science workshop: targeting the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2016 , 31, 1327-1337.	3.9	16
130	Does the death of a spouse increase subjective well-being: An assessment in a population of adults with neurological illness. <i>Healthy Aging Research</i> , 2016 , 5, 1-9	1	3
129	Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e187	4.2	48
128	HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 638-43	6.1	38
127	Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. <i>Scientific Reports</i> , 2016 , 6, 26800	4.9	107
126	Neurological examination. <i>Clinical Liver Disease</i> , 2016 , 7, 151-153	2.2	
125	Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 78-86	0.7	87
124	Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43 Suppl 1, 11-26	6.1	69
123	In Patients With Cirrhosis, Driving Simulator Performance Is Associated With Real-life Driving. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 747-52	6.9	11
122	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016 , 64, 717-35	13.4	183
121	Liver transplantation significantly improves global functioning and cerebral processing. <i>Liver Transplantation</i> , 2016 , 22, 1379-90	4.5	24
120	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016 , 64, 200-8	11.2	137

119	Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. <i>Hepatology</i> , 2016 , 64, 1232-48	11.2	56
118	Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis. <i>Seminars in Liver Disease</i> , 2016 , 36, 327-330	7.3	24
117	Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis. <i>Scientific Reports</i> , 2016 , 6, 38481	4.9	39
116	Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS norms. <i>Metabolic Brain Disease</i> , 2016 , 31, 1199-203	3.9	4
115	Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary. <i>Metabolic Brain Disease</i> , 2016 , 31, 1081-93	3.9	13
114	Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2048-61	6.9	105
113	Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 987-91	6.9	23
112	The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. <i>Acta Pharmaceutica Sinica B</i> , 2015 , 5, 99-105	15.5	104
111	Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. <i>Hepatology</i> , 2015 , 62, 1260-71	11.2	178
110	Decompensated cirrhosis and microbiome interpretation. <i>Nature</i> , 2015 , 525, E1-2	50.4	72
109	Covert and Overt Hepatic Encephalopathy: Current Options for Diagnosis and Treatment. <i>Current Hepatology Reports</i> , 2015 , 14, 234-242	1	1
108	Reply: To PMID 25130937. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2028	6.9	
107	Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. <i>Journal of Hepatology</i> , 2015 , 62, 75-82	13.4	53
106	Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 753-9.e1-2	6.9	81
105	Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 39-45	6.1	35
104	Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. <i>Gastroenterology</i> , 2015 , 148, 203-214.e16	13.3	193
103	Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1828-1835.e1	6.9	81
102	What Is the ethical (Not Legal) responsibility of a physician to treat minimal hepatic encephalopathy and advise patients not to drive?. <i>Clinical Liver Disease</i> , 2015 , 6, 86-89	2.2	3

101	Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. <i>Scientific Reports</i> , 2015 , 5, 18559	4.9	53
100	Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , 2015 , 62, 1923-4	11.2	13
99	High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease. <i>Liver Transplantation</i> , 2015 , 21, 881-8	4.5	47
98	The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. <i>Liver Transplantation</i> , 2015 , 21, 1123-32	4.5	29
97	Liver capsule: Hepatic encephalopathy. <i>Hepatology</i> , 2015 , 62, 955	11.2	1
96	Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. <i>Digestive Diseases</i> , 2015 , 33, 338-45	3.2	58
95	Shared symptoms and putative biological mechanisms in chronic liver disease: implications for biobehavioral research. <i>Biological Research for Nursing</i> , 2015 , 17, 222-9	2.6	3
94	Microbiome and complications of liver disease. <i>Clinical Liver Disease</i> , 2015 , 5, 96-99	2.2	3
93	The Relationship Between the Gut Microbiota and Liver Disease. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 626-8	0.7	1
92	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014 , 60, 250-6	11.2	317
91	Altered profile of human gut microbiome is associated with cirrhosis and its complications. <i>Journal of Hepatology</i> , 2014 , 60, 940-7	13.4	587
90	Useful tests for hepatic encephalopathy in clinical practice. <i>Current Gastroenterology Reports</i> , 2014 , 16, 362	5	29
89	Commentary: Probing probiotics in cirrhosis--a template for future studies? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1335-6	6.1	1
88	Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1757-63	0.7	111
87	Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1113-25	6.1	176
86	Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2014 , 29, 1017-25	3.9	53
85	Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. <i>Hepatology</i> , 2014 , 60, 715-35	11.2	997
84	A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. <i>Journal of Lipid Research</i> , 2014 , 55, 978-90	6.3	78

83	Colonic inflammation and secondary bile acids in alcoholic cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 306, G929-37	5.1	112
82	Diagnosis of covert hepatic encephalopathy without specialized tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1384-1389.e2	6.9	43
81	Elevated liver enzymes following polytraumatic injury. <i>Journal of Rehabilitation Research and Development</i> , 2014 , 51, 869-74		9
80	Commentary: TIPSS for Budd-Chiari syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1237-8		1
79	Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, G951-7	5.1	107
78	Bile acids and the gut microbiome. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 332-8	3	663
77	The role of microbiota in hepatic encephalopathy. <i>Gut Microbes</i> , 2014 , 5, 397-403	8.8	100
76	Antibiotics for the treatment of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013 , 28, 307-12	3.9	64
75	Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. <i>Journal of Hepatology</i> , 2013 , 58, 949-55	13.4	444
74	The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. <i>Hepatology</i> , 2013 , 58, 1122-32	11.2	128
73	Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. <i>Journal of Hepatology</i> , 2013 , 59, 467-73	13.4	36
72	Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. <i>Journal of Hepatology</i> , 2013 , 58, 38-44	13.4	19
71	Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 407-14	6.1	13
70	New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. <i>Gastroenterology</i> , 2013 , 145, 1280-8.e1	13.3	175
69	Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. <i>Liver International</i> , 2013 , 33, 1324-31	7.9	46
68	Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1511-6	6.9	40
67	Effect of obstructive sleep apnea on the sleep architecture in cirrhosis. <i>Journal of Clinical Sleep Medicine</i> , 2013 , 9, 247-51	3.1	12
66	The Relationship between Marital Status and Psychological Resilience in Chronic Pain. <i>Pain Research and Treatment</i> , 2013 , 2013, 928473	1.9	16

65	Statin use and infections in Veterans with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 611-8	6.1	31
64	Commentary: non-haemodynamic effects of beta-blockers in cirrhosis - more than meets the eye? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 653	6.1	
63	Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. <i>Gut Microbes</i> , 2013 , 4, 382-7	8.8	207
62	Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. <i>PLoS ONE</i> , 2013 , 8, e60042	3.7	253
61	Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 866-74	6.1	74
60	Driving simulation can improve insight into impaired driving skills in cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 554-60	4	13
59	Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012 , 56, 2328-35	11.2	269
58	Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. <i>Liver Transplantation</i> , 2012 , 18, 1179-87	4.5	25
57	Assessment of minimal hepatic encephalopathy (with emphasis on computerized psychometric tests). <i>Clinics in Liver Disease</i> , 2012 , 16, 43-55	4.6	16
56	Covert hepatic encephalopathy: not as minimal as you might think. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1208-19	6.9	56
55	Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. <i>European Journal of Internal Medicine</i> , 2012 , 23, 37-9	3.9	5
54	Commentary: PPIs and risk of serious infection in decompensated cirrhosis AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 1095-1095	6.1	5
53	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012 , 61, 1219-25	19.2	68
52	Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. <i>Hepatology</i> , 2012 , 55, 1164-71	11.2	91
51	A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2012 , 27, 205-15	3.9	72
50	Modified-orientation log to assess hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 913-20	6.1	21
49	The Intestinal Microbiota and Liver Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012 , 1, 9-14		30
48	Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, G675-85	5.1	331

47	Reply to Parikh and Butt. <i>American Journal of Gastroenterology</i> , 2012 , 107, 486-487	0.7	1
46	Linkage of gut microbiome with cognition in hepatic encephalopathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, G168-75	5.1	330
45	What is driving the legal interest in hepatic encephalopathy?. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 97-8	6.9	9
44	Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. <i>Gastroenterology</i> , 2011 , 140, 478-487.e1	13.3	154
43	Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 739-47	6.1	222
42	Disruption of sleep architecture in minimal hepatic encephalopathy and ghrelin secretion. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 103-5	6.1	14
41	PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1123-32	6.1	57
40	Advances in the evaluation and management of minimal hepatic encephalopathy. <i>Current Gastroenterology Reports</i> , 2011 , 13, 26-33	5	30
39	Diet and cognition in chronic liver disease. <i>Current Opinion in Gastroenterology</i> , 2011 , 27, 174-9	3	23
38	The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1646-53	0.7	220
37	Review article: the modern management of hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 537-47	6.1	168
36	Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1012-7	6.1	69
35	<i>Clostridium difficile</i> is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. <i>American Journal of Gastroenterology</i> , 2010 , 105, 106-13	0.7	127
34	Pathogenesis and diagnosis of hepatic encephalopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010 , 4, 365-78	4.2	32
33	Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. <i>Gastroenterology</i> , 2010 , 138, 2332-40	13.3	209
32	Current and future diagnosis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2010 , 25, 107-10	3.9	10
31	Drug therapy: rifaximin. <i>Hepatology</i> , 2010 , 52, 1484-8	11.2	32
30	The effect of fatigue on driving skills in patients with hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2009 , 104, 898-905	0.7	47

29	Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. <i>Hepatology</i> , 2009 , 50, 1175-83	11.2	213
28	Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. <i>Hepatology</i> , 2009 , 50, 2014-21	11.2	233
27	Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1130-4	0.7	149
26	Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. <i>Gastroenterology</i> , 2008 , 135, 1591-1600.e1	13.3	164
25	Probiotic yogurt for the treatment of minimal hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1707-15	0.7	194
24	Patients with minimal hepatic encephalopathy have poor insight into their driving skills. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1135-9; quiz 1065	6.9	49
23	Management options for minimal hepatic encephalopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 785-90	4.2	44
22	Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1674-81	0.7	27
21	Endoscopic band ligation of esophageal varices in patients on anticoagulation. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42, 782-5	3	8
20	Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. <i>Hepatology</i> , 2008 , 47, 596-604	11.2	106
19	Failure to fully disclose during pretransplant psychological evaluation in alcoholic liver disease: a driving under the influence corroboration study. <i>Liver Transplantation</i> , 2008 , 14, 1632-6	4.5	10
18	Safety and feasibility of evaluating airway-protective reflexes during sleep: new technique and preliminary results. <i>Gastrointestinal Endoscopy</i> , 2007 , 65, 483-6	5.2	3
17	Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: a pilot study. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2190-4	4	36
16	The role of endoscopy in noniatrogenic injuries of the liver. <i>Current Gastroenterology Reports</i> , 2007 , 9, 147-50	5	3
15	Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1903-9	0.7	128
14	Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2007 , 102, 754-60	0.7	110
13	Impact of <i>Clostridium difficile</i> on inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 345-51	6.9	425
12	In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2006 , 23, 377-84	3.6	17

11	Influence of sleep stages on esophago-upper esophageal sphincter contractile reflex and secondary esophageal peristalsis. <i>Gastroenterology</i> , 2006 , 130, 17-25	13.3	39
10	Postoperative management of noniatrogenic traumatic bile duct injuries: role of endoscopic retrograde cholangiopancreatography. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2006 , 20, 974-7	5.2	21
9	Another indication for transnasal, unsedated upper-GI endoscopy. <i>Gastrointestinal Endoscopy</i> , 2005 , 62, 667-8	5.2	4
8	MELD score does not discriminate against patients with hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 753-6	4	16
7	Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1121-5	0.7	62
6	Esophageal veggie spasms: a food-specific cause of chest distress. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1396-8	0.7	1
5	High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 1189-93	6.1	19
4	The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 1925-8	4	25
3	Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C. <i>Gastrointestinal Endoscopy</i> , 2003 , 58, 380-3	5.2	3
2	Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001 , 16, 641-6	4	44
1	Conformational basis of the receptor-binding potency of normal and mutant insulin molecules with relevance to the pathophysiology of noninsulin dependent diabetes mellitus (NIDDM). <i>International Journal of Quantum Chemistry</i> , 1988 , 34, 95-101	2.1	